Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda to Use Amgen Japanas Development Subsidiary
February 18, 2008
- No Problems Found in EPPV of Velcade, Alimta
February 18, 2008
- Repeat Consultation Fee for Clinics Will Not Be Cut: Chuikyo
February 11, 2008
- Actemra to Be Approved for RA
February 11, 2008
- REGULATORY NEWS IN BRIEF
February 11, 2008
- Japan Should Take Part in More Multinational Clinical Trials: JMACCT Conference
February 11, 2008
- Live Vaccine Development Important for New-type Influenza
February 11, 2008
- R&D NEWS IN BRIEF
February 11, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 11, 2008
- TOPICS／Merck Seiyaku Renamed Mylan Seiyaku
February 11, 2008
- Chugai's Sunrise 2012 Plan Calls For Sales of \460 Bil.
February 11, 2008
- Takeda Acquires Amgen in Japan
February 11, 2008
- NEW PRODUCTS／Bayer Launches EOB Primovist for MRI of the Liver
February 11, 2008
- Mediceo Paltac to Embark on Generics Business in Earnest
February 11, 2008
- BUSINESS NEWS IN BRIEF
February 11, 2008
- Shigeo Oyagi Elected President, CEO of Teijin Limited
February 11, 2008
- All ARBs, SSRIs to Be Re-priced
February 11, 2008
- Council Moving to Build Up Regional Clinical Trial Systems
February 4, 2008
- NEW PRODUCTS
February 4, 2008
- Public Opinions Invited on Draft Guidance on MD Studies
February 4, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…